SMS Pharmaceuticals DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.86×	0.87×	0.75×	0.75×	−1.32×
	0.90×	0.89×	0.88×	0.78×	0.24×
	14.8%	14.8%	13.4%	12.0%	4.3%
	0.71×	0.71×	0.72×	0.74×	0.60×
	1.73×	1.73×	1.80×	1.93×	1.91×
	14.0%	14.2%	11.5%	10.0%	−1.5%
	14.3%	14.3%	11.7%	10.0%	−1.5%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SMSPHARMA₹475.45

SMS Pharmaceuticals Limited

· Pharma & Health

₹ CrorePeersINDSWFTLAB SOLARA DCAL UNICHEMLAB GUFICBIO RPGLIFE HIKAL GUJTHEMMcap ₹4,453 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	-1.32	0.75	0.75	0.87	0.86
Interest Burden (Pretax/EBIT) ×	0.24	0.78	0.88	0.89	0.90
EBIT Margin %	4.29	12.00	13.37	14.81	14.78
Asset Turnover ×	0.60	0.74	0.72	0.71	0.71
Financial Leverage (Assets/Equity) ×	1.91	1.93	1.80	1.73	1.73
ROE (5-step product, year-end total equity) %	-1.55	10.02	11.46	14.16	14.04
ROE (owners' profit / average owners' equity) %	-1.52	10.00	11.67	14.32	14.32

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.